iNOVA4Health Seminar “Engineering the tumor cell niche to study dormancy and drug resistance in metastatic breast cancer” by Shreyas Rao

Engineering the Tumor Cell Niche to Study Dormancy and Drug Resistance in Metastatic Breast Cancer

On June 6th, iBET had the pleasure of welcoming Shreyas Rao for the iNOVA4Health Seminar “Engineering the tumor cell niche to study dormancy and drug resistance in metastatic breast cancer”.

Prof. Shreyas Rao is an Associate Professor of Chemical and Biological Engineering at the University of Alabama (Tuscaloosa, USA). His research focuses on developing engineering tools to explore the role of tumor microenvironment in cancer progression, therapeutic response and resistance.

During his seminar, Prof. Rao presented his team’s latest work on biomimetic in vitro models, developed using biomaterial scaffolds, to investigate cancer dormancy and drug resistance, particularly in brain metastatic breast cancer.

These engineered systems aim to uncover strategies to re-educate the tumor microenvironment, potentially offering new strategies to halt disease progression and improve patient outcomes.

iBET was also delighted to welcome a group of undergraduate students from the University of Alabama, currently completing a short-term research placement at iBET as part of a Summer Exchange Program organized by Prof. John Kim.

We extend our sincere appreciation to Prof. Rao for his inspiring talk and sharing his valuable expertise with our community.

Related news

Advanced 3D Cell Models for Preclinical Research: iBET Welcomes Visit and Seminar by Dr. Eckhard von Keutz
March 4, 2026

Antibody-Drug Conjugates Landscape, Challenges and Opportunities: iBET Welcomes Dr. John Lambert
December 12, 2025

Emerging Innovations in Baculovirus Expression Vector System (BEVS): iBET Hosts iNOVA4Health Seminar by Dr. Imre Berger
November 19, 2025

iBET Hosts iNOVA4Health Insightful Seminars on Biotherapeutics Manufacturing Processes by Dr. Lee and Dr. Lakshmanan
October 24, 2025

iBET Hosts Boehringer Ingelheim’s Global Head for Biotherapeutics Discovery for Cancer Immunotherapy Seminar
October 16, 2025